{"id":"mp513","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce airway inflammation and improve lung function in obstructive airway diseases.","oneSentence":"MP513 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:12.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT02220907","phase":"PHASE3","title":"Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":153},{"nctId":"NCT00971243","phase":"PHASE2","title":"Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":448},{"nctId":"NCT02354235","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT02354222","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT01026194","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":204},{"nctId":"NCT02314637","phase":"PHASE3","title":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT00628212","phase":"PHASE2","title":"Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT00998881","phase":"PHASE3","title":"Monotherapy Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":203},{"nctId":"NCT02081599","phase":"PHASE4","title":"Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-01","conditions":"Type 2 Diabetes Mellitus","enrollment":148},{"nctId":"NCT01072331","phase":"PHASE3","title":"Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT01301833","phase":"PHASE3","title":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-02","conditions":"Type 2 Diabetes Mellitus","enrollment":462},{"nctId":"NCT03787017","phase":"PHASE1","title":"A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2014-01","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT03787043","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food on Fixed-Dose Combination of MP-513 10 mg and Metformin XR 750 mg","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT01805830","phase":"PHASE3","title":"Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-05","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT01798238","phase":"PHASE3","title":"Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-11","conditions":"Type 2 Diabetes Mellitus","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MP513","genericName":"MP513","companyName":"Handok Inc.","companyId":"handok-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MP513 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}